Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to assess current practice patterns and barriers surrounding bispecific antibody treatment and adverse event management in eligible patients with R/R DLBCL in community oncology settings
Upon completion of this activity, participants should be better able to differentiate new and emerging bispecific antibodies for R/R DLBCL based on the latest clinical safety and efficacy
Upon completion of this activity, participants should be better able to align clinical practice with expert recommendations for the prompt recognition and management of adverse events associated with bispecific antibodies for R/R DLBCL, including cytokine release syndrome and neurotoxicity
Upon completion of this activity, participants should be better able to develop and integrate evidence-based workflows for the mitigation, recognition, and management of bispecific antibody-related adverse events to guide the safe delivery and integration of bispecific antibodies into individualized treatment plans for patients with R/R DLBCL